Clinical trials: Cytarabine, completed
Relapsed Acute Leukemia, Refractory Acute Leukemia
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Based on what is known about it's mechanism of action, bortezomib is presumed to make other chemotherapy drugs work better. This study examines the use of bortezomib in combination with an already effective chemotherapy regimen…
- Trial name
- NCT00410423
- Testing
- Bortezomib with mitoxantrone, etoposide and cytarabine, Bortezomib 1.0mg/m^2, Bortezomib 1.3mg/m^2
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Lymphoblastic Leukemia
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Current therapeutic protocols for adult ALL consider MRD together with the baseline risk factors (age, WBC count, immunophenotype, cytogenetics) and speed in response to therapy for treatment decisions.
- Trial name
- LAL-AR/2003 (NCT00853008)
- Testing
- Vincristine, Daunorubicin, Prednisone
- Where
- 38 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Leukemia, Myeloid, Acute
BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment
Investigation of maximum tolerated dose, safety, efficacy and pharmcokinetics of BI 811283 in combination with cytarabine (LD-Ara-C) in previously untreated acute myeloid leukaemia (AML) patients
- Trial name
- NCT00632749
- Testing
- BI 811283 (d 1 and 15), Cytarabine, BI 811283 (d1)
- Where
- 7 sites in Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
Leukemia
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells.
- Trial name
- NCT00022126
- Testing
- asparaginase, cyclophosphamide, cyclosporine
- Where
- 51 sites in United States, Australia and 1 more
- Volunteers
- 6 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia (AML)
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation
This is a randomized, Phase-III, two-arm, open-label, multi-center study in adult patients with AML and NPM1 mutation ineligible for intensive chemotherapy.
- Trial name
- NCT01237808
- Testing
- Cytarabine, Etoposide, All-trans retinoic acid (ATRA)
- Where
- 33 sites in Germany
- Volunteers
- 144 people
- Sponsor
- University of Ulm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL)…
- Trial name
- NCT03384654
- Testing
- Daratumumab, Vincristine, Prednisone
- Where
- 53 sites in United States, Belgium and 8 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Myelodysplastic Syndrome
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
The purpose of this study is to find a safe dose of actinium-225 when it is labeled to HuM195. This will be done with a "phase I trial," in which a preset schedule of doses gets more powerful for each new group of patients as the…
- Trial name
- NCT00672165
- Testing
- ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating patients who have chronic myelogenous leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Relapsing Chronic Myelogenous Leukemia
- Trial name
- NCT00015834
- Testing
- imatinib mesylate, cytarabine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloid, Isocitrate Dehydrogenase
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML)…
- Trial name
- IDHENTIFY (NCT02577406)
- Testing
- AG-221, BSC, Azacitidine
- Where
- 93 sites in United States, Australia and 16 more
- Volunteers
- 319 people
- Sponsor
- Celgene
Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The goal of this trial is to evaluate the efficacy and the tolerance of the combination of nilotinib with chemotherapy in the front-line setting as induction and consolidation therapy in Ph+ ALL patient aged 55 years and over.
- Trial name
- NCT01528085
- Testing
- Nilotinib
- Where
- 69 sites in France, Germany and 1 more
- Volunteers
- 79 people
- Sponsor
- Goethe University
Follicular Lymphoma
High-Dose Therapy Treatment in Patients With Follicular Lymphoma
Follicular lymphomas are a subgroup of B-cell non-Hodgkin lymphomas, accounting for 15% to 30% of newly diagnosed lymphomas.1-3 Median survival varies from 5 to 10 years depending on the prognostic factors at diagnosis and…
- Trial name
- NCT00696735
- Testing
- chemotherapy, high dose therapy and autologous stem cell transplantation
- Where
- 2 sites in France
- Volunteers
- 172 people
- Sponsor
- French Innovative Leukemia Organisation
Lymphoma
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
The overall goal of this clinical research study was to find out which of two different chemotherapy drug combinations, R-CHOP and R-HCVAD, is more effective in treating B-cell lymphoma.
- Trial name
- NCT00290498
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndrome, Acute Myeloblastic Leukemia
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
Association group of therapeutic specialities authorized in a remission induction treatment(FLAG-IDA: fludarabine, cytarabine, G-CSF (lenograstim) and idarubicin) and an intensive postremission treatment with authorized…
- Trial name
- FLAG-IDA (NCT00487448)
- Testing
- Fludarabine, Cytarabine, G-CSF
- Where
- 15 sites in Spain
- Volunteers
- 200 people
- Sponsor
- PETHEMA Foundation
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002638
- Testing
- filgrastim, sargramostim, carmustine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Nebraska
Lymphoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003311
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
This phase I trial studies the side effects and the best dose of selinexor when give together with standard chemotherapy, high dose cytarabine and mitoxantrone hydrochloride, in treating patients with acute myeloid leukemia.
- Trial name
- NCT02573363
- Testing
- Cytarabine, Mitoxantrone Hydrochloride, Selinexor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Chicago
ACUTE MYELOGENOUS LEUKEMIA
High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML
Determine the effects of escalated dose of daunorubicin in induction treatment of adult patients with acute myelogenous leukemia who are younger than 60 years of age.
- Trial name
- ADcomparison (NCT00474006)
- Testing
- arm II
- Where
- South Korea
- Volunteers
- 398 people
- Sponsor
- Cooperative Study Group A for Hematology
Leukemia
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005793
- Testing
- Cytarabine, Daunorubicin, Etoposide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Primary Objectives: 1. To determine the response rate, progression-free survival (PFS) and overall survival of patients who receive 2-CdA + Ara-C. 2.
- Trial name
- NCT00483067
- Testing
- 2-CdA, Ara-C, G-CSF (Granulocyte colony-stimulating factor)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk
Patients with de novo AML enrolled in the study. Patient who has a HLA-identical donor is assigned to receive NST therapy with GVHD prophylaxis and who has no HLA-identical donor is assigned to receive MST therapy without GVHD…
- Trial name
- NCT02461121
- Testing
- HLA mismatched stem cell, HLA matched stem cell, cyclosporine A
- Where
- China
- Volunteers
- 156 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences